Novartis: Pipeline Reinforcement and an Event-Driven Upside Near-Term
Novartis ($156.74) is actively rebuilding its innovation engine with bolt-on M&A and late-stage assets. A clinical readout for a late-stage program (pelacarsen) is expected imminently, and the company just agreed to acquire Myricx Bio for up to $1.5 billion (07/06/2026) to beef up its ADC payload capabilities. We view the risk/reward as favorable f…